Search Results 1-10 of 28335 for ������������������������������������������r���:PC53���
The Infection and Immunity Lab of Raymund R. Razonable, M.D., at Mayo Clinic studies COVID-19 and transplant-related infections such as cytomegalovirus ...
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's ...
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive.
The purpose of this study is to assess the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R ...
This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical activity, predictive biomarkers and pharmacokinetics/ pharmacodynamics of ...
The purpose of this study is to determine safety and tolerability of orally delivered R-3750 in mild to moderate patients with ulcerative colitis. Participation ...
Darci R. Block, Ph.D. Chemist. Request an Appointment · Overview · Publications. Publications. Print. Chandrasekar AP, Wang Q, Block DR. "It's Pink!". Clin Chem ...
Close up of IV drip for patient and Infusion pump in hospital. ROCHESTER, Minn. — The targeted therapy everolimus may be safely combined with R-CHOP for new, ...
Subjects will be randomized 1:1 to R-CHOP plus enzastaurin or R CHOP (plus placebo during induction). All subjects will receive up to 6 cycles (3 weeks per ...
The purpose of this study is to compare the effectiveness and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift can go twice as far to advance cancer research and care!